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Abstract
Background:   W e  i n v e s t i g a t e d  t h e  c h e m o p r e v e n t i v e  a c t i o n  o f  d i e t a r y  c u r c u m i n  o n  7 , 1 2 -
dimethylbenz(a)anthracene  (DMBA)-initiated  and  12,0-tetradecanoylphorbol-13-acetate  (TPA)-
promoted skin tumor formation in Swiss albino mice. Curcumin, a yellow coloring matter isolated
from roots of Curcuma longa Linn, is a phenolic compound possessing antioxidant, free radical
scavenger, and antiinflammatory properties. It has been shown by previously reported work that
TPA-induced skin tumors were inhibited by topical application of curcumin, and curcumin has been
shown to inhibit a variety of biological activities of TPA. Topical application of curcumin was
reported to inhibit TPA-induced c-fos, c-jun and c-myc gene expression in mouse skin. This paper
reports the effects of orally administered curcumin, which was consumed as a dietary component
at concentrations of 0.2 % or 1 %, in ad libitum feeding.
Results:  Animal s in which tumors  had be en init iat ed  with DMBA and promote d wit h T PA
experienced significantly fewer tumors and less tumor volume if they ingested either 0.2% or 1%
curcumin diets. Also, the dietary consumption of curcumin resulted in a significantly decreased
expression of ras  and  fos proto-oncogenes in the  tumorous skin,  as measured  by enhanced
chemiluminesence Western blotting detection system (Amersham).
Conclusions:  Whereas earlier work demonstrated that topical application of curcumin to mouse
skin inhibited TPA-induced expression of c-fos, c-jun and c-myc oncogenes, our results are the first
to show that orally consumed curcumin significantly inhibited DMBA- and TPA-induced ras and fos
gene expression in mouse skin.
Background
Curcumin is yellow coloring matter isolated from roots of
Curcuma longa Linn commonly called turmeric. It has
been widely used in many Asian countries as a spice, to
color cheese and butter, as a cosmetic and in some me-
dicinal preparations. Curcumin (diferuloylmethane), a
phenolic compound, possesses antioxidant, free radical
scavenger and anti-inflammatory properties [1,2,3,4,5].
Several works in epidemiology and animal model studies
demonstrated that compounds which possess antioxi-
dant or anti-inflammatory properties can inhibit car-
cinogenesis [6,7,8,9]. One of the classic models is the
inhibition of 12-0-tetradecanoylphorbol-13-acetate
(TPA)-induced tumor promotion in mouse skin. TPA is a
strong promoter of chemically induced skin cancer. It
has been shown that TPA-induced skin tumors were in-
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hibited by topical application of curcumin [10,11]. Curcu-
min can inhibit the activity of cytochrome P450 and
increase GSH content in rat liver which help to explain
anticarcinogenic, antimutagenic and cytoprotective ef-
fects of curcumin [12,13]. Many reports have shown that
curcumin inhibits a variety of biological activities of TPA,
which induces several biosynthetic processes, namely in-
duction of ornithine decarboxylase [10], elevation or
translocation of protein kinase C [14], induction of cy-
clooxygenase and lipooxygenase [11]. Topical application
of curcumin inhibits TPA-induced c-fos, c-jun, c-myc
gene expression on mouse skin after 2 hours of TPA
treatment [15]. In present studies, we investigated the
modulating effect of dietary curcumin on DMBA and
TPA-induced tumor formation and on the expression
levels of ras-p21 and fos-p62 to provide an understand-
ing of the molecular basis of the relationship between the
dietary curcumin and transforming function of oncogen-
ic ras and fos during multi-stage skin carcinogenesis.
Results
Effect of dietary curcumin on the tumorigenesis of DMBA 
and TPA
Fig. 1 shows the changes in body weight. There was no
significant difference in body weight changes between
the control and 1 or 0.2% curcumin treated groups (P >
0.05). The effect of dietary curcumin on the tumorigene-
sis of DMBA and TPA was evaluated using the two-stage
mouse skin model. Animals receiving a single topical ap-
plication of DMBA, followed by 26 weeks of promotion
with TPA, when fed the control diet, developed 7.7 ±  1.4
papillomas/mouse (Fig. 2). The number of papillomas
was significantly lower in the 1% and 0.2% curcumin diet
group than in the control group (P < 0.05) dose depend-
ent manner. Fig. 3 shows the average volume of tumors
per mouse in the curcumin diet compared to the control
group. The average volume was significantly lower in the
1% or 0.2% curcumin diet than in the control group (P <
0.01) dose dependently. No papillomas were observed in
the groups which received the control diet or the diet
supplemented with 1% or 0.2% curcumin or the vehicle
with no application of DMBA and TPA.
Differential expression of ras-p21 and fos-p62
Fig. 4a and 4b demonstrates the representative examples
of Western blot analysis of membrane-bound ras-p21
and nuclear fos-p62 protein. The samples exhibited de-
tectable levels of p21 with c-Ha- anti-ras-21 mouse mon-
oclonal antibody and levels of p62 with anti-fos-62
rabbit polyclonal antibody. Regardless of dietary regi-
men, very low (background) levels of ras-p21 and fos-
p62 were detected in acetone treated animals (data not
shown). The mice receiving a single topical application of
DMBA, followed by 26 weeks of promotion with TPA de-
veloped increasing higher levels of skin ras-p21 and fos-
p62 expression in all dietary groups. Skin tumors exhib-
ited higher levels of ras-p21 and fos-p62 than the normal
skin. The enhanced expression of the ras-p21 and fos-
p62 in skin tumors was decreased by curcumin diets of
1% and 0.2% dose dependently as compared with ras-p21
or fos-p62 in the mouse counterparts on control diet (p <
0.05).
Figure 1
Changes in body weight in Swiss mice treated with control, 0.2% and 1% curcumin diets. Each point represents the mean value
(N=20).BMC Cancer (2001) 1:1 http://www.biomedcentral.com/1471-2407/1/1
Table 1. summarizes the densitometric analysis of differ-
ential expression of ras-p21 and fos-p62 in tumorous and
non-tomorous skin of DMBA and TPA-treated animals
fed the control, 1 or 0.2% curcumin diets.
Discussion
Results of this study demonstrate that 0.2% or 1% dietary
curcumin inhibit the DMBA- and TPA-induced en-
hanced expression of ras and fos oncogenes and suppress
skin tumor development. Previously, data from our lab-
oratory have demonstrated that animals fed high
amounts of dietary curcumin (1%) had significantly low-
er multiplicity of TPA-induced skin papillomas com-
pared with their counterparts ingesting control diet [16].
So in the present study we demonstrated the inhibition
of tumor development at the lower concentration of cur-
Figure 2
Average number of tumors per mouse in Swiss mice treated with control, 0.2% and 1% curcumin diet. Each point represents
the mean value (N=20).
Figure 3
Average volume of tumors per mouse in Swiss mice treated with control, 0.2% and 1% curcumin diets. Each point represents
the mean value (N=20).BMC Cancer (2001) 1:1 http://www.biomedcentral.com/1471-2407/1/1
cumin (0.2%) to minimize the possibility of overcon-
sumption of curcumin. Our previous data (not shown
here) has shown that at higher concentration of curcu-
min (2%) did not show as good inhibitory effect as the
lower concentration (1%). It may due to the second effect
of curcumin which may not be of benefit for prevention
of carcinogenesis. Our results are in agreement with oth-
er reports on the inhibitory action of turmeric or curcu-
min on carcinogenesis in different experimental designs.
Azuine and Bhide demostrated that Swiss mice with mul-
tiple doses of DMBA for eight weeks applied on their
back and fed 2% turmeric diet developed less tumors
than those fed standard diet [17]. Curcumin has already
been linked to lower rates of forestomach, duodenal and
colon cancer. Administration of 0.5-2% curcumin in the
diet decreased the number and size of benzopyrene-in-
duced forestomach tumors in A/J mice, N-ethyl-N'-ni-
trosoguanidine-induced duodenal tumorigenesis and
azoxymethane induced colon tumorigenesis in CF-1 mice
[18]. A 1% turmeric diet suppressed benz(a)pyrene-in-
duced forestomach tumors and spontaneous mammary
tumors in mice [19]. Dietary curcumin at the concentra-
tion of 500 ppm (equivalent to 0.05%) inhibited 4-nitro-
quinoline 1-oxide induced oral carcinogenesis in F344
rats [20].
Conclusion
Kakar and Roy [15] demonstrated that topical applica-
tion of curcumin on mouse skin inhibited TPA induced
expression of c-fos, c-jun and c-myc oncogene. Our re-
sults are the first report which demonstrate that dietary
curcumin significantly inhibited DMBA- and TPA-in-
duced ras and fos gene expressions in mouse skin. Cur-
cumin may block a certain point on the signal
transduction pathway leading to fos and ras oncogene
expression.
Materials and methods
Chemicals
DMBA and TPA were purchased from Sigma (St.Louis,
MO, USA). Commercial curcumin (77% curcumin, 17%
demethoxycurcumin, and 3% bisdemethoxy curcumin,
Fig. 5) was purchased from ICN Biomedical (Costa Mesa,
CA, USA). Feed ingredients (casein, methionine, mineral
and vitamin mixtures, cellulose and choline bitartate)
were purchased from ICN Biomedical. All other chemi-
cals were of AR grade.
Figure 4
Analysis of ras p-21 and fos p-62 oncogenes expression. a =
Western blot analysis of ras-21 using anti ras-21 mouse mon-
oclonal antibody b = Western blot analysis of fos-p62 using
anti fos-62 rabbit polyclonal antibody Lane 1 = Control diet
Lane 2 = 1% Curcumin diet Lane 3 = 0.2% Curcumin diet T =
Tumorous skin; N = Non-tumorous skin
Table 1: Effect of dietary curcumin on expression levels of c-Ha-ras (p21) and c-fos (p62) in skin of DMBA and TPA treated animals (N 
= 20).
Condition Ras (Arbitary unit) Fos (Arbitary unit)
TN T N
Control 8.74 ±  1.7 0.17 ±  0.1 5.8 ±  0.8 0.8 ±  0.5
(100%) (1.94%) (100%) (13.8%)
0.2%Curcumin 5.30 ±  2.2 0.15 ±  0.05 3.6 ±  0.9 0.9 ±  0.15
(60.6%) (1.72%) (62.1%) (15.5%)
1%Curcumin 2.73 ±  1.1 0.07 ±  0.05 2.0 ±  0.6 0
(31.2%) (0.8%) (34.5%) (0%)
T = Tumorous skin N = Non-tumorous skin aResults are expressed as arbitary unit; values are mean ±  SD. bValues in parentheses relatively represent 
percentage of ras or fos gene expression. The levels of ras and fos proteins in the control diet are represented as 100%.BMC Cancer (2001) 1:1 http://www.biomedcentral.com/1471-2407/1/1
Animals
Male Swiss albino mice, 5 weeks old, were purchased
from the National Laboratory Animal Center, Thailand.
All diet ingredients were stored at 4° C prior to the prep-
aration of diets. The mice were quarantined for 7 days
and had access to modified AIN-76A diet. Following
quarantine, all the mice were randomly distributed by
weight into various groups and were housed individually
under controlled conditions of a 12-h light/12-h dark cy-
cle and 22 ±  2° C.
Diets and treatments
In all treatment groups the mice were fed a modified
AIN-76 diet (control diet). The control diet had the fol-
lowing composition (g/100 g): 20 casein, 0.3 DL-me-
thionine, 3.5 mineral, 1 vitamin, 5 cellulose, 5 corn oil, 32
corn starch, 33 sucrose, and 0.2 choline bitartrate. In
some treatment groups, the control diet was modified by
the addition of 1% or 0.2% curcumin (Table 2). The in-
corporation of curcumin into the diet was done with a V-
blender after curcumin was premixed with a small quan-
tity of diet in a food mixer to ensure its uniform distribu-
tion. All feeds were pelleted to avoid stratification and to
ensure uniform feed and curcumin intake in the treated
animals. All control and experimental diets were pre-
pared every 2 weeks in our laboratory and stored at -
20° C before use. The mice had access to food and water
at all times, and food cups were replenished with fresh
diet three times weekly.
As indicated in Fig. 6, beginning at 6 weeks of age,
groups of animals were fed the control diet or the exper-
imental diet containing 1% or 0.2% curcumin. At 8 weeks
of age, groups of animals were started on carcinogen
treatment. The mice were sorted into the following treat-
ment groups (20 mice/group). One group of mice were
fed the control diet and treated with DMBA and TPA on
the skin. Some groups of animal were fed the control diet
supplemented with 1% or 0.2% curcumin and similarly
treated with DMBA and TPA. The vehicle (acetone sol-
vent) chemical control groups were fed the control diet
or the curcumin diet and treated with acetone on the
skin. Animals were maintained on control or curcumin
diets until the termination of the experiment. The backs
of mice were shaved with electric clippers 3 days before
the first skin treatment and thereafter were shaved when
needed for the duration of the experiment. Carcinogen or
vehicle solvent (acetone) was applied to the dorsal
shaved area.
All of the animals which were subjected to tumor initia-
tion and promotion received 100 µ g of 7, 12-dimethyl-
benz [a]anthracene (DMBA) dissolved in 100 µ l of
acetone in a single application to the skin of the back.
From 1 week after DMBA application, tumor promoter,
2.5 µ g of 12-0-tetradecanoyllphorbol-13-acetate (TPA)
dissolved in 100 µ l of acetone, was applied to the same
areas on mouse skin twice a week for 26 weeks (Fig. 2).
The vehicle control groups received only 100 µ l of ace-
tone to the skin of the back. Mice were weighed at weekly
intervals. Tumors appearing on mouse skin were count-
ed and measured by a Pierre Vernier caliper weekly
throughout week 26. The average tumor volume was cal-
Figure 5
Curcuminoid compounds Curcumin: R1 = R2 = OCH3 (77%)
Desmethoxycurcumin: R1 = H , R 2 =  OCH3  (17%)  Bisdes-
methoxycurcumin: R1 = R2 = H (3%)
Table 2: Experimental Diets.
Ingredients Control diet (%) Curcumin supplement (%)
(Groups 1a, 2a)* (Groups 1b, 1c, 2b, 2c)*
Casein 20 19 or 19.8
Curcumin 0 1 or 0.2
DL-methionine 0.3 0.3
Mineral mixture 3.5 3.5
Vitamin mixture 1.0 1.0
Cellulose 5.0 5.0
Starch 32.0 32.0
Sucrose 33.0 33.0
Choline Bitartate 0.2 0.2
Corn oil 5.0 5.0
*Group 1a, 1b and 1c = DMBA and TPA treated mice Group 2a, 2b 
and 2c = acetone treated mice (chemical control of group 1) a = Con-
trol diet, b = 1% Curcumin diet, c = 0.2% Curcumin dietBMC Cancer (2001) 1:1 http://www.biomedcentral.com/1471-2407/1/1
culated as (length) ×  (width) ×  (height) π /6. The data
were analyzed by Student's t-test and chi-square test.
Determination of c-fos and c-Ha-ras gene expression
After 26 weeks of TPA application, pooled tumors and
non-tumorous mouse epidermis from each experimental
group (control diet, 1 and 0.2% curcumin diet) were col-
lected. The skins were excised and placed in a water bath
at 60° C for 30s and then submerged in liquid nitrogen
[21]. The tumors were rapidly removed and frozen in liq-
uid nitrogen and the non-tumorous epidermis was re-
moved from the dermis by gentle scraping and then
rapidly frozen in liquid nitrogen. The samples were
stored at - 70° C until used for western blot analysis. The
c-fos and c-Ha-ras proteins were analyzed by enhanced
chemiluminescence (ECL) Western blot analysis using
specific anti-p62 fos and anti-p21 ras antibodies, respec-
tively.
Preparations of Ha-ras-p21 and fos-p62 proteins
The pooled tumors and nontumorous mouse epidermis
from each experimental group (control diet, 1 and 0.2%
curcumin diets) were washed with cold phosphate buffer
saline and suspended in 1 ml of buffer A (20 mM Tris-
HCl, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 1 mM DTT, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 20 µ g/ml apro-
tinin, and 10 µ g/ml leupeptin). The suspension was ho-
mogenized in a glass homogenizer with 30 strokes and
centrifuged at 700 g for 5 min to remove unbroken cells
and nuclei. The nuclear pellet was used for fos prepara-
tion. The supernatant was further centrifuged at
100,000 g for 30 min. The membrane pellet was resus-
pended in 1 ml of buffer B (1% NP-40, 0.5% sodium de-
oxycholate, 0.1%SDS, 0.6 mM PMSF and 1 mM sodium
orthovanadate in PBS pH 7.4), rocked for 1 h, and then
centrifuged at 100,000 g for 30 min. The supernatant
was used as membrane fraction for ras-p21 analysis and
stored as aliquots at -80° C.
The nuclear extract was prepared by the method of Dig-
nam et al. [22] as follows: the pellet obtained from the
low speed centrifugation of the homogenate was resus-
pended in buffer C (20 mM HEPES pH 7.9, 25% glycerol,
0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
PMSF, 0.5 mM DTT) and was stirred gently with a mag-
netic stirring bar for 30 min at 4° C and then centrifuged
for 30 min at 25,000 g (Sorval SS34 rotor), and the su-
pernatant was dialysed against 50 volumes of buffer D
(20 mM HEPES pH 7.9, 20% glycerol, 0.1 M KCl, 0.2 mM
EDTA, 0.5 mM PMSF, 0.5 mM DTT) for 5 h. The dia-
lysate was centrifuged for 20 min at 25,000 g (Sorval
SS34 rotor) and the resulting precipitate discarded. The
supernatant, designated the nuclear extract, was frozen
as aliquots in liquid nitrogen and stored at -80° C.
The protein contents in both nuclear and membrane
fractions were determined with Bio-Rad reagent.
Immunodetection and quantification of ras-p21 and fos p-
62 using ECL Western blot
SDS-PAGE and Western transfers were carried out es-
sentially by the methods of Laemmli [23] and Towbin et
al [24]. Nuclear and membrane extracts corresponding
to 25 µ g of protein were solubilized in Laemmli's sample
buffer. Samples were boiled for 3 min and resolved by ex-
tended electrophoresis on a 12.5% polyacrylamide mini-
slab gel containing SDS with an overlay of 4% polyacry-
lamide, along with prestained SDS-PAGE molecular
weight markers and the ras-p21 Western blot standards
(Oncogene Science, Manhasset, NY). Electrophoretically
resolved proteins were electrotransferred onto Hybond
Figure 6
Experimental design for evaluation of chemopreventive efficacy by curcumin. Carcinogen: 100 µ g of DMBA in 100 µ l of acetone
in a single application. 2.5 µ g of TPA dissolved in 100 µ l of acetone, twice a week for 26 weeks. Experimental diets: 0.2 and 1%
curcuminBMC Cancer (2001) 1:1 http://www.biomedcentral.com/1471-2407/1/1
ECL membrane in a Trans-blot electrophoretic transfer
cell (Bio-Rad Laboratories).
After transblotting the electrophoretically resolved pro-
teins, the blots were blocked with 5% nonfat dry milk dis-
solved in Tris-buffered saline containing 0.2% Tween-20
(TBST). Blots were then incubated with specific mono-
clonal antibody to c-Ha-ras protein (Santa Cruz Biotech-
nology) diluted in TBST and reincubated with
peroxidase-linked secondary antibody (antimouse IgG;
Amersham) diluted in TBST containing 0.5% nonfat dry
milk. The blots were then throughly washed in excess
TBST and probed with the ECL. Western blot detection
system (Amersham) using reflection autoradiography
films was performed according to the manufacturer's in-
structions. The autoradiograms were scanned with an
Image Master sharp laser densitometric scanner, and the
peak areas representing ras-p21 bands were determined.
Western blot analysis of the fos protein was performed
by the same protocol as described above except in the de-
tection system, the specific antibody to c-fos p62 protein
(Santa Cruz Biotechnology) was used instead of specific
antibody to ras-p21 protein.
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